Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-12-20
1996-05-28
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 46, 514579, 514588, 536 2714, 536 278, A61K 3170
Patent
active
055211615
ABSTRACT:
A method and composition for inhibiting the spread of a retrovirus such as HIV in a human cell population in which a retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.
REFERENCES:
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5110600 (1992-05-01), Green
patent: 5300059 (1994-04-01), Rubinstein et al.
U.S. application Ser. No. 08/065,814 filed May 21, 1993, Lorie et al.
Medina et al., "Ganciclovir Antagonizes the Anti-Human-Immunodeficiency Virus Type I Activity of Zidovudine and Didanosine In Vitro," Antimicrobial Agents and Chemotherapy, 36(5), 1127-1130 (1992).
"Study Puts Risk of H.I.V. In Young U.S. Men at 1 in 92," New York Times, (National Ed.), Nov. 24, 1995, p. B19.
Simonelli et al., "Hydroxyurea as an Antiretroviral Drug in HIV Infected Patients: Clinical, Immunological and Virological Evaluation," Abstract No. 84 in Book of Abstracts from The Fifth European Conference on Clinical Aspects and Treatment of HIV Infection, European AIDS Clinical Society (publ.), Copenhagen, Denmark, Sep. 26-29, 1995.
L. K. Altman, "Study Challenges AZT Roll As the Chief Drug for H.I.V., " New York Times, (Sec. 1), Sunday, Sep. 17, 1995, p. 38.
Langreth, "FDA Gives Approval to Glaxo, Sequus To Market Separate AIDS Therapies," The Wall Street Journal, Nov. 21, 1995, p. B12.
Meyerhans et al, "The Intracellular Nucleotide Pool Effects HIV Replication", VIII International Conference on AIDS/III STD World Congress, vol. 2, Jul. 1992, p. A22-2118.
T'Ang et al, "Optimization of the Schiff Bases of N-Hydroxy-N'-aminoguanidine as Anticancer and Antiviral Agents", J. Med. Chem., vol. 28, 1985, pp. 1103-1106.
Lien,"Ribonucleotide reductase inhibitors as anticancer and antiviral agents", Progress in Drug Research, vol. 31, 1987, pp. 101-126.
Lori et al, "Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1", Antiviral Res., vol. 23/Sup. 1, 1994, p. 63.
Gao et al, "Anti-HIV-1 Activity of Hydroxyurea in Combination with 2',3'-dideoxynucleosides", Clinical Research, vol. 42, No. 2, 1994, p. 280A.
Matsumoto et al, "Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycoformycin in Resting Lymphocytes", The Journal of Immunology, vol. 131, 1983, pp. 2762-2766.
International Search Report for Internation Application No. PCT/US 94/05515.
Balzarini et al, "2',3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis", Molecular Pharmacology, vol. 32, 1987, pp. 798-806.
Saffrin et al, "Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection", Journal of Medical Virology Supplement 1, 1993, pp. 146-149.
Wilson et al, "Purinogenic Immunodeficicency Diseases--Differential Effects of Deoxyadenosine and Deoxyguanosine on DNA Synthesis in Human T Lymphoblasts", J. Clin. Invest., vol. 64, 1979, pp. 1475-1484.
Albert et al, "Deoxyadenosine Toxicity and Cell Cycle Arrest in Hydroxurea-Resistant S49 T-Lymphoma Cells", Experimental Cell Research, vol. 179, 1988, pp. 417-428.
Perno et al, "Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-III.sub.Ba-L) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2',3'-Dideoxynucleosides", J. of Exp. Medicine, vol. 168, 1988, pp. 1111-1125.
Fischl, "Treatment of HIV Disease in 1993/1994", AIDS Clin. Rev., vol. 94, 1993, pp. 167-187.
Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," Eur. J. Biochem., 186, 689-694 (1989).
Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in DNA Repaiet al. r and Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33, especially pp. 25-28.
Hao et al., "Factors Determining the Activity of 2',3'-Dideoxynucleosides in Suppressing Human Immunodeficiency Virus In Vitro," Molecular Pharmacology, 34, 431-435 (1988).
Malley et al., "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds," The Lancet, 343(8908), 1292 (1994).
Biron et al., "Anti-HIV Activity of the Combination of Didanosine and Hydroxurea in HIV-1 Infected Individuals," J. AIDS and Human Retrovirology, 10(1), 1-4[preprint] (Aug. 1995).
Lori et al., "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," Science, 266, 801-805 (4 Nov. 1994).
Balzarini et al., "The Anti-HTLV-III (Anti-HIV) and Cytotoxic Activity of 2'-3'-didehydro-2',3'-dideoxyribonucleosides: A Comparison with Their Parental 2',3'-Dideoxyribonucleosides," Molecular Pharmacology, 32, 162-167 (1987).
Gao et al., "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy of Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. Nat. Acad. Sci. USA, 90, 8925-8928 (1990).
Biochemicals/Organic Compounds for Research and Diagnostic Reagents, Sigma Chemial Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
Feorino et al., "Prevention of Activation of HIV-1 by Anitiviral Agents in OM-10.1 Cells," Antiviral Chemistry & Chemotherapy, 4(1), 55-63 (1993).
Snyder et al., "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," Mol. Pharmacol., 28(6), 5745-580 (1985); Chem Abstr., 104(9), p. 30, Abstr. No. 61633w (1986).
Licastro et al., "Inhibition of Polymerases-60 and -.beta. Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," Biochem. Biophys. Res. Comm., 132(3), 929-933 (1985).
Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).
R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I," Genetic Engineering News, Sep. 1, 1992, pp. 4-6.
R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II," Genetic Engineering News, Sep. 15, 1992, pp. 4-5.
Center for Disease Control, "Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men--New York City and California," Morbidity and Mortality Weekly Report, 30(25), 305-308 (Jul. 3, 1981).
Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)" Science, 220, 868-870 (1983).
Fauci(I), "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," Science, 239, 617-622 (1988).
Fauci (II), "Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," Science, 262:1011-1018 (1993).
Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," Cell, 61, 213-222 (1990).
Bukrinsky et al., "Quiescent T Lymphocytes as a Inducible Virus Reservoir in HIV-1 Infection," Science, 245, 423-427 (1989).
Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is a Cell That Maintains Expression of CD4," Science, 245, 305-308 (1989).
Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human Immunodeficiency Virus Type 1 RNA," J. Infectious Diseases, 164, 1051-1057 (1991).
Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection," New Engl. J. Med., 328, 1686-1695 (1993).
Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," J. Virological Methods, 20, 309-321 (1988).
Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2',3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," N. Engl. J. Med., 321, 726-738 (1989).
Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," Nature, 361, 650-654
Malley Serge D.
Vila Jorge R.
Compagnie de Developpment Aguettant S.A.
Crane L. Eric
Robinson Douglas W.
LandOfFree
Method of treating HIV in humans by administration of ddI and hy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating HIV in humans by administration of ddI and hy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating HIV in humans by administration of ddI and hy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-786765